… SMT022357, is a second-generation compound structurally related to ezutromid, sharing
the same mechanism of action but with improved physicochemical properties and a more …

… Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy
(DMD), … The ability of the compounds to increase utrophin levels was investigated using the …

… insights regarding utrophin upregulation as a strategy for DMD therapeutic intervention. …
the second generation phosphinates. Compound 1 was also found to increase utrophin mRNA …

… of another second-generation utrophin modulator SMT022357 … candidacy of SG-02 for DMD
therapy. Our data suggest that … lead compounds exhibited a significant elevation in utrophin …

… Furthermore, GA-binding protein can enhance utrophin promoter activity … Therefore,
therapeutic strategies that modulate the … ) are a class of compounds that function by inhibiting the …

… therapies, exon skipping, and readthrough therapy, as well as strategies that target secondary
pathology of DMD, such as novel anti-inflammatory compounds, … of utrophin appeared to …

… second-generation drugs now entering in clinical trials as gene … , utrophin modulation
remains a promising therapeutic … Anti-inflammatory factors, utrophin upregulators, compounds/…

… genes such as utrophin and combination therapies, are also … currently exon skipping, whereby
modulation of splicing is used … 3d), with the leading compound AOC 1044, targeting DMD …

… utrophin domains in Duchenne muscular dystrophy treatment, providing insights into designing
novel therapeutic compounds … with multiple roles in modulating various cell functions, …

… Transgenic mice overexpressing utrophin showed its localization … of utrophin-based therapies
applicable to all DMD patients … that utrophin-based strategies such as utrophin modulation …